A Study of the Efficacy and Safety of TACI-antibody Fusion Protein Injection (RC18) in Subjects With Inadequate Response to TNF-α Antagonists Due to Treat Moderate and Severe Rheumatoid Arthritis
Clinical trial NCT02882087 · TERMINATED
Trial details
- NCT number
- NCT02882087
- Sponsor
- RemeGen Co., Ltd.
- Status
- TERMINATED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2015-10-01
- Primary completion
- 2019-02-25
- Enrollment
- 60
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.